Betahistine dihydrochloride

CLINICAL USE

Treatment of vertigo, tinnitus and hearing loss associated with Ménière’s syndrome

DOSE IN NORMAL RENAL FUNCTION

8–16 mg, 3 times a day

PHARMACOKINETICS

Molecular weight :209.1

%Protein binding :0–5

%Excreted unchanged in urine : 85–90

Volume of distribution (L/kg) :No data

half-life – normal/ESRD (hrs) :3.4/–

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : 8–16 mg, 2–3 times a day

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Likely dialysability. Dose as in GFR <10 mL/min

HD :Likely dialysability. Dose as in GFR <10 mL/min

HDF/high flux :Likely dialysability. Dose as in GFR <10 mL/min

CAV/VVHD :Likely dialysability. Dose as in GFR 10 to 20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsNone known

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Betahistine is rapidly and completely absorbed after oral administration

It is excreted almost exclusively in the urine as 2-pyridylacetic acid within 24 hours of administration

Tags: post-by-auto-php